UDJ Stock Overview A biotechnology company, develops and commercializes technologies to produce and detect deoxyribonucleic acid (DNA) in the Americas, Europe, Asia, and internationally. More details
Rewards Risk Analysis + 3 more risks
See All Risk Checks Capture your thoughts, links and company narrative
Applied DNA Sciences, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Applied DNA Sciences Historical stock prices Current Share Price US$4.66 52 Week High US$33.22 52 Week Low US$4.66 Beta 0.082 1 Month Change 0% 3 Month Change -21.02% 1 Year Change -81.24% 3 Year Change -94.91% 5 Year Change -97.64% Change since IPO -99.98%
Recent News & Updates Applied DNA Sciences, Inc. Auditor Raises 'Going Concern' Doubt Dec 19
Applied DNA Sciences, Inc. Customer ÚHKT Initiates Phase I Clinical Trial for Rapidly Manufacturable CAR T-Cell Therapy Produced from Linea DNA Dec 18
Applied DNA Sciences, Inc. to Report Q4, 2024 Results on Dec 17, 2024 Dec 16
Applied DNA Sciences, Inc. Receives Written Notice from Nasdaq Regarding Minimum Bid Price Requirement Nov 13 Applied DNA Sciences, Inc. announced that it has received funding Nov 01
Applied DNA Sciences, Inc. has filed a Follow-on Equity Offering in the amount of $6.499893 million. See more updates Applied DNA Sciences, Inc. Auditor Raises 'Going Concern' Doubt Dec 19
Applied DNA Sciences, Inc. Customer ÚHKT Initiates Phase I Clinical Trial for Rapidly Manufacturable CAR T-Cell Therapy Produced from Linea DNA Dec 18
Applied DNA Sciences, Inc. to Report Q4, 2024 Results on Dec 17, 2024 Dec 16
Applied DNA Sciences, Inc. Receives Written Notice from Nasdaq Regarding Minimum Bid Price Requirement Nov 13 Applied DNA Sciences, Inc. announced that it has received funding Nov 01
Applied DNA Sciences, Inc. has filed a Follow-on Equity Offering in the amount of $6.499893 million.
Applied DNA Regains Compliance with Nasdaq Minimum Bid Price Requirement Sep 18
Applied DNA Sciences, Inc.'s Applied DNA Clinical Labs, LLC Launches Mpox Clade I and Clade II Testing Service Sep 11
Applied DNA Sciences, Inc. to Submit Application to New York State Department of Health to Expand Intended Use of Linea Mpox Virus 1.0 Assay to Mpox Clade I Aug 20
Applied DNA Sciences, Inc. to Report Q3, 2024 Results on Aug 08, 2024 Aug 07
Applied DNA Sciences, Inc., Annual General Meeting, Sep 30, 2024 Aug 06
Applied DNA Sciences Receives Non-Compliance Notice from Nasdaq Regarding Minimum Bid Price Requirement Jul 16
Applied DNA Sciences, Inc. Receives Approval for TR8(TM) Pharmacogenomic (PGx) Testing Service from New York State Department of Health Jun 14
Applied DNA Sciences, Inc. has completed a Composite Units Offering in the amount of $12 million. May 31 Applied DNA Sciences, Inc. has completed a Composite Units Offering in the amount of $12 million. May 30
Applied DNA Sciences, Inc. Receives A Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC May 17
Applied DNA Regains Compliance with Nasdaq Minimum Bid Price Requirement May 11 Applied DNA Sciences, Inc. has filed a Follow-on Equity Offering.
Applied DNA Sciences, Inc. to Showcase Linea DNA and Linea IVT Platforms At 24Th Annual World Vaccine Congress Mar 15
First quarter 2024 earnings released: US$0.075 loss per share (vs US$0.30 loss in 1Q 2023) Feb 09
New major risk - Shareholder dilution Feb 07
Applied DNA Sciences, Inc. to Report Q1, 2024 Results on Feb 08, 2024 Feb 06 Applied DNA Sciences, Inc., Annual General Meeting, Apr 15, 2024 Applied DNA Sciences, Inc. has filed a Follow-on Equity Offering in the amount of $3.436992 million. Feb 01
Applied DNA Sciences, Inc. has filed a Follow-on Equity Offering in the amount of $3.437233 million.
New major risk - Revenue and earnings growth Dec 12
Full year 2023 earnings released: US$0.76 loss per share (vs US$0.93 loss in FY 2022) Dec 08
Applied DNA Sciences Receives Non-Compliance Notice From Nasdaq Dec 07
Applied DNA Sciences, Inc. to Report Q4, 2023 Results on Dec 07, 2023 Dec 06
Applied DNA Sciences, Inc. Extends Application of Linea(Tm) Ivt Platform to Sna (Self-Amplifying Mrna) Nov 17
Applied DNA Sciences, Inc. has filed a Follow-on Equity Offering in the amount of $6.397939 million. Nov 09 Applied DNA Sciences, Inc. has filed a Follow-on Equity Offering in the amount of $6.397939 million. Nov 08
Applied DNA Sciences, Inc. Announces Appointment of Beverly Wolgast as Executive Director of Quality and cGMP Programs
Applied DNA Sciences, Inc. Announces Availability and First Customer Shipment of New Linea(TM) IVT Evaluation Kit Aug 30
Applied DNA Sciences, Inc. Files Provisional Patent Applications for Methods of Double-Stranded RNA Mitigation in Next-Generation mRNA Production Aug 24
Third quarter 2023 earnings released: US$0.24 loss per share (vs US$0.13 loss in 3Q 2022) Aug 13
Applied DNA Sciences, Inc. to Report Q3, 2023 Results on Aug 10, 2023 Aug 08
Applied DNA Sciences, Inc., Annual General Meeting, Sep 19, 2023 Aug 03
Applied DNA Sciences, Inc. (NasdaqCM:APDN) acquired Spindle Biotech Inc. for $2.8 million. Jul 14
New major risk - Share price stability Jun 08
Second quarter 2023 earnings released: EPS: US$0.046 (vs US$0.23 loss in 2Q 2022) May 14
Applied DNA Sciences, Inc. to Report Q2, 2023 Results on May 11, 2023 May 04
First quarter 2023 earnings released: US$0.30 loss per share (vs US$0.63 loss in 1Q 2022) Feb 10
Applied DNA Sciences, Inc. to Report Q1, 2023 Results on Feb 09, 2023 Feb 03
Applied DNA Sciences, Inc. Announces Publication of Peer-Reviewed Journal Article Validating Potential Use of linearDNA as New Class of DNA-Based Vaccines Jan 06
Full year 2022 earnings released: US$0.93 loss per share (vs US$2.07 loss in FY 2021) Dec 15
Insufficient new directors Dec 02
Applied DNA Sciences, Inc. to Report Q4, 2022 Results on Dec 05, 2022 Nov 04
Applied DNA Sciences, Inc.'s Subsidiary, Applied DNA Clinical Labs, LLC, Launches Monkeypox Testing Service Sep 07
Applied DNA Submits PCR-Based Monkeypox Virus Diagnostic Test for Approval to New York State Department of Health Aug 20
Third quarter 2022 earnings released: US$0.13 loss per share (vs US$0.46 loss in 3Q 2021) Aug 13 Applied DNA Sciences, Inc. Announces Retirement of John Bitzer from Board of Directors
Applied DNA Sciences, Inc. Launches Initiatives to Expand Awareness of LinearDNA Platform as Alternative to Plasmid DNA for Therapeutic Applications, Revamps LineaRx Website Jun 30
Applied DNA and Evvivax Announce Peer-Reviewed Publication of Positive Preclinical Data for LinearDNA Platform Jun 07
Second quarter 2022 earnings released: US$0.23 loss per share (vs US$0.21 loss in 2Q 2021) May 14 Applied DNA Sciences, Inc. to Report Q2, 2022 Results on May 12, 2022 May 10
Applied DNA Sciences, Inc. and EvviVax, S.R.L. Announce Publication of Positive Preclinical Data for LinearDNA™ Platform Approach to Cancer Immunotherapy Feb 18
First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat Feb 11
Applied DNA Sciences, Inc. to Report Q1, 2022 Results on Feb 10, 2022 Feb 04
Applied DNA Sciences, Inc. to Deploy Linea™ 1.0 COVID-19 Assay for Rapid Detection of New Omicron Subvariant BA.2 Jan 30
Applied DNA Clinical Labs Receives New York State Department of Health Conditional Approval for Linea™ 2.0 COVID-19 Assay as Laboratory Developed Test Jan 05
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Dec 10
No longer forecast to breakeven Nov 24
Forecast to breakeven in 2023 Sep 23
Third quarter 2021 earnings released: US$0.46 loss per share (vs US$0.72 loss in 3Q 2020) Aug 14
Applied DNA Sciences and A&E Introduce Anti-Counterfeiting Technology for Sustainable Sewing Threads Jun 09
Applied DNA Sciences, Inc. and Evvivax, S.R.L. Announce Results from in Vitro Neutralization Study of Sera Jun 08
Applied DNA Completes Technical Validation of PCR-based SARS-CoV-2 Mutation-Detection Panel, Highlights Ability to Rapidly Identify Mutations and Probable Variants May 27
Second quarter 2021 earnings released: US$0.21 loss per share (vs US$0.79 loss in 2Q 2020) May 16
Applied Dna Sciences, Inc. Clarifies the Scope of Its Newly Authorized Asymptomatic Serial Screening Indication for Its Linea Covid-19 Assay Kit May 14
FDA Grants EUA to Applied DNA LineaTM COVID-19 Assay Kit for Asymptomatic Screening of Individuals with Serial Testing May 13 Shareholder Returns UDJ DE Life Sciences DE Market 7D 0% -3.1% -2.0% 1Y -81.2% -5.9% 6.9%
See full shareholder returns
Return vs Market: UDJ underperformed the German Market which returned 0.9% over the past year.
Price Volatility Is UDJ's price volatile compared to industry and market? UDJ volatility UDJ Average Weekly Movement n/a Life Sciences Industry Average Movement 7.1% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.3% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: UDJ's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine UDJ's volatility change over the past year.
About the Company Applied DNA Sciences, Inc., a biotechnology company, develops and commercializes technologies to produce and detect deoxyribonucleic acid (DNA) in the Americas, Europe, Asia, and internationally. It operates through three segments: Therapeutic DNA Production Services; MDx Testing Services; and DNA Tagging and Security Products and Services. The Therapeutic DNA Production Services segment develops and commercializes the LinearDNA platform, which enables a cell-free manufacture of high-fidelity synthetic DNA sequences for use in nucleic acid-based therapeutics.
Show more Applied DNA Sciences, Inc. Fundamentals Summary How do Applied DNA Sciences's earnings and revenue compare to its market cap? UDJ fundamental statistics Market cap €3.78m Earnings (TTM ) -€11.48m Revenue (TTM ) €5.07m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) UDJ income statement (TTM ) Revenue US$5.52m Cost of Revenue US$3.64m Gross Profit US$1.88m Other Expenses US$14.38m Earnings -US$12.50m
Last Reported Earnings
Mar 31, 2024
Earnings per share (EPS) -1.22 Gross Margin 33.98% Net Profit Margin -226.55% Debt/Equity Ratio 0%
How did UDJ perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/07/22 17:39 End of Day Share Price 2024/04/24 00:00 Earnings 2024/03/31 Annual Earnings 2023/09/30
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Applied DNA Sciences, Inc. is covered by 7 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Jan Wald Benchmark Company Matthew Miller CFRA Equity Research Yi Chen H.C. Wainwright & Co.
Show 4 more analysts 
